| Diabetes Mellitus, Non-Insulin-Dependent
Kombiglyze XR vs Lipitor
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Kombiglyze vs Lipitor with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLipitor has a higher rate of injection site reactions vs Kombiglyze based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lipitor but not Kombiglyze, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Kombiglyze
Lipitor
At A Glance
Oral
Once daily
DPP4 inhibitor + biguanide
Oral
Daily
HMG-CoA reductase inhibitor (statin)
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Myocardial Infarction
- Cerebrovascular accident
- Stable angina
- Diabetes Mellitus, Non-Insulin-Dependent
- Congestive heart failure
- Hyperlipidemia
- Familial hypercholesterolemia - heterozygous
- Homozygous Familial Hypercholesterolemia
- Hyperlipoproteinemia Type III
- Hypertriglyceridemia
Dosing
Diabetes Mellitus, Non-Insulin-Dependent Administer once daily with the evening meal; individualize starting dose based on current regimen; max 5 mg saxagliptin/2,000 mg metformin HCl extended-release once daily; limit saxagliptin to 2.5 mg daily with strong CYP3A4/5 inhibitors; swallow tablets whole.
Myocardial Infarction, Cerebrovascular accident, Stable angina, Diabetes Mellitus Non-Insulin-Dependent, Congestive heart failure, Hyperlipidemia, Hyperlipoproteinemia Type III, Hypertriglyceridemia 10 or 20 mg once daily starting; range 10-80 mg once daily; patients requiring LDL-C reduction >45% may start at 40 mg once daily; oral.
Familial hypercholesterolemia - heterozygous Adults: 10 or 20 mg once daily, range 10-80 mg once daily; pediatric patients aged >=10 years: 10 mg once daily starting, range 10-20 mg once daily; oral.
Homozygous Familial Hypercholesterolemia Adults: 10 or 20 mg once daily, range 10-80 mg once daily; pediatric patients aged >=10 years: 10-20 mg once daily starting, range 10-80 mg once daily; oral.
Contraindications
- Severe renal impairment (eGFR below 30 mL/min/1.73 m2)
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
- History of serious hypersensitivity reaction to saxagliptin, metformin HCl, or any ingredient in KOMBIGLYZE XR, including anaphylaxis, angioedema, or exfoliative skin conditions
- Acute liver failure or decompensated cirrhosis
- Hypersensitivity to atorvastatin or any excipient in Lipitor
Adverse Reactions
Most common (>=5%) Upper respiratory tract infection, urinary tract infection, headache (saxagliptin); diarrhea, nausea/vomiting (metformin)
Serious Lactic acidosis, pancreatitis, heart failure, hypoglycemia with insulin or insulin secretagogues, hypersensitivity reactions, severe and disabling arthralgia, bullous pemphigoid, vitamin B12 decrease
Postmarketing Pancreatitis, anaphylaxis, angioedema, exfoliative skin conditions, rhabdomyolysis, bullous pemphigoid, cholestatic and hepatocellular liver injury
Most common (>=2%) Nasopharyngitis, arthralgia, diarrhea, pain in extremity, urinary tract infection, dyspepsia, nausea, musculoskeletal pain, muscle spasms, myalgia, insomnia, pharyngolaryngeal pain
Serious Myopathy and rhabdomyolysis, immune-mediated necrotizing myopathy, hepatic dysfunction, increases in HbA1c and fasting serum glucose
Postmarketing Pancreatitis, fatigue, fatal and non-fatal hepatic failure, anaphylaxis, tendon rupture, rhabdomyolysis, myositis, dizziness, peripheral neuropathy, cognitive impairment, myasthenia gravis exacerbation, depression, interstitial lung disease, angioneurotic edema, bullous rashes
Pharmacology
Kombiglyze XR combines saxagliptin, a competitive DPP4 inhibitor that slows incretin hormone (GLP-1, GIP) inactivation to enhance glucose-dependent insulin release and suppress glucagon, and metformin HCl, a biguanide that decreases hepatic glucose production, reduces intestinal glucose absorption, and improves peripheral insulin sensitivity.
Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of cholesterol; it lowers plasma LDL cholesterol and lipoprotein levels by inhibiting hepatic cholesterol synthesis and upregulating LDL receptor expression on hepatic cell surfaces.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Kombiglyze
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Lipitor
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (1/12)
UnitedHealthcare
Kombiglyze
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (7/8)
Lipitor
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Kombiglyze
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (3/3)
Lipitor
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Kombiglyze.
No savings programs available for Lipitor.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
KombiglyzeView full Kombiglyze profile
LipitorView full Lipitor profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.